Infusystem Hld Stock Price, News & Analysis

InfuSystem Holdings, Inc. (NYSE: INFU) announced a 9% revenue increase for Q1 2022, totaling $26.8 million. Growth was driven by a 5% rise in Integrated Therapy Services and an 18% rise in Durable Medical Equipment Services. Although gross profit rose to $15.4 million, the gross margin decreased to 57.4%. InfuSystem signed a three-year Master Service Agreement with a leading medical technology company, potentially generating $10-12 million in annual revenue. Operating cash flow surged 54% to $4.1 million, but a net loss of $0.4 million was reported. The company expects 15-20% revenue growth for the full year.

InfuSystem Holdings, Inc. (NYSE American: INFU) has secured a three-year master service agreement with a leading global healthcare technology company, effective April 25, 2022. This agreement involves providing maintenance and repair services for over 300,000 infusion pumps across more than 1,200 medical facilities in North America. The estimated annual revenue from this contract is between $10 million and $12 million. The CEO emphasizes this partnership as a foundation for growth in their Durable Medical Equipment (DME) services segment.

InfuSystem Holdings, Inc. (NYSE American: INFU) will release its first quarter 2022 financial results on May 5, 2022, before market opening. A conference call will follow at 9:00 a.m. Eastern Time for discussion of the results. Interested parties can participate by calling (888) 567-1603 or via live webcast at the company's website. InfuSystem specializes in outpatient care for durable medical equipment, operating through its Integrated Therapy Services and Durable Medical Equipment Services platforms.

InfuSystem Holdings, Inc. (NYSE American: INFU) has announced a national distribution agreement with Solo-Dex, Inc. for its continuous nerve block catheters, enhancing acute pain management capabilities. This technology allows anesthesiologists to insert catheters in two to three minutes for major procedures, potentially improving patient recovery while reducing reliance on opioids. The collaboration is aimed at capturing a significantly larger market, estimated to be ten times the current nerve catheter market. The joint effort aims to establish a new standard of care in pain management.

InfuSystem Holdings reported financial results for 2021, with net revenues at $102.4 million, a 5% increase from 2020. The fourth quarter saw revenues of $26.5 million, up 7.3% year-over-year. Despite this growth, net income dropped to $0.4 million, significantly lower than $10.7 million in Q4 2020. The gross margin decreased to 57.7%. Management anticipates 20% revenue growth in 2022, driven by pain management and a pending biomedical services contract expected to add $8-$12 million in revenue.

InfuSystem Holdings (NYSE: INFU) will announce preliminary fourth quarter and full year 2021 financial results on February 10, 2022, before the market opens. A conference call will follow the announcement at 9:00 a.m. Eastern Time to discuss these results. The company specializes in facilitating outpatient care for durable medical equipment through its Integrated Therapy Services and Durable Medical Equipment Services platforms. Interested parties can participate via phone or listen through a live webcast on the company’s investor relations website.

InfuSystem Holdings, Inc. (NYSE American: INFU) will present at the Sidoti Winter Virtual Investor Conference on January 19, 2022, at 8:30 a.m. ET. Key executives, including CEO Richard DiIorio, CFO Barry Steele, and COO Carrie Lachance, will lead the presentation.

A webcast will be available on their website, and a replay will follow the event. Investors can also engage in one-on-one meetings by contacting Lytham Partners.

InfuSystem Holdings (NYSE American: INFU) reported third-quarter 2021 net revenues of $26.6 million, a 6% increase year-over-year. The company anticipates $14-15 million in annual revenue from a new biomedical services contract, alongside growth in Pain Management services. Despite a net loss of $0.4 million and a 27% decline in Adjusted EBITDA, management is optimistic about future growth, reaffirming full-year revenue guidance of $107-110 million. Operating cash flow increased by 15% to $14.6 million.

InfuSystem Holdings, Inc. will release its Q3 2021 financial results on November 15, 2021, before market opens. A conference call is scheduled for the same day at 9:00 a.m. Eastern Time to discuss the results. Interested parties can participate by calling (833) 366-1127 or through a live webcast available on the company’s website. InfuSystem is a leading provider of health care services, focusing on integrated therapy services and durable medical equipment.